The radiopharma space is once again in the spotlight with another big pharmaceutical name buying a clinical-stage oncology company focused on developing radioconjugates, or RCs. AstraZeneca (AZN) announced… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3884627/-This-radiopharma-name-seen-as-poised-for-takeout-following-Fusion-deal)
previous post